Our patents


Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia has patent protection for the treatment of a large number of different cancer forms using antibodies directed against IL1RAP. Cantargia also has a patent family covering the product candidates nadunolimab (CAN04) and CAN10, as well as several patent families covering other antibodies targeting IL1RAP. Cantargia's patent strategy is global, and covers markets deemed to be of clinical and commercial relevance for the product pipeline.

Patent varldskarta
Patent family Patent application Approved patents Validity
Nadunolimab (Product) USA Australia, Brasil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Great Britain, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey), India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA 2035
CAN10 (Product) Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, South Africa, South Korea, USA USA 2041
Leukemias (Treatment) USA 2029
Hematological cancers (Treatment/Diagnosis) China Australia, Canada, China, Europe (France, Germany, Great Britain, Italy, Netherlands, Spain, Switzerland), Israel, Japan, Mexico, South Africa, USA 2030
Solid tumors (Treatment/Diagnosis) China, Europe Australia, Brazil, Canada, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland), Japan, Mexico, South Korea, USA 2032
CAN03 (Product) China, Europe (France, Germany, UK), Japan, USA 2035
Anti-IL1RAP antibodies (Product) Europe China, Japan, USA 2037
Biepitopic antibody (Product) China, Japan, USA Europe 2039